KMT2A rearranged B lineage infant ALL cell line SEM treated with bortezomib LC-MS/MS

ABSTRACT: The KMT2A rearranged B lineage infant ALL cell line SEM was treated with the proteasome inhibitor bortezomib followed by a multiplexed mass spectrometry-based proteomic analysis at multiple time points (0, 6, 12, 16, and 20 hours) over 20 hours to further understand the cellular response of these cells to proteasome inhibition.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Blood

DISEASE(S): Acute Leukemia

SUBMITTER: Vishwajeeth Pagala  

LAB HEAD: Tanja A. Gruber

PROVIDER: PXD038845 | Pride | 2023-02-15

REPOSITORIES: Pride